JNJ-42847922 40 mg

DRUG2 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Healthy

Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

CompletedNCT02230878

Janssen-Cilag International NVHealthy

Start: 2014-05-31End: 2014-11-30Updated: 2017-01-24

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

CompletedNCT02837692

Janssen Research & Development, LLCHealthy

Start: 2016-06-08End: 2017-09-11Updated: 2017-10-30